Clinical Trial Update: Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants

View source ↗

Summary

Biogen's Canadian multicenter observational study of natalizumab (Tysabri) in patients with early Relapsing-Remitting Multiple Sclerosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis | Status: TERMINATED